Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 17/20 | 0.50 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15050015 | 0.90 | PTGER1 (0.61) | PTGER1CYP1A2 | |
| SCHEMBL15049972 | 0.87 | PTGER1 (0.54) | PTGER1 | |
| SCHEMBL15050019 | 0.87 | PTGER1 (0.54) | PTGER1CYP1A2 | |
| SCHEMBL15049945 | 0.85 | PTGER1 (0.54) | PTGER1CYP1A2 | |
| SCHEMBL4091719 | 0.83 | PTGER1 (0.56) | PTGER1 | |
| SCHEMBL248695 | 0.83 | PTGER1 (0.47) | PTGER1SCN8ASCN10A | |
| SCHEMBL15050228 | 0.79 | PTGER1 (0.47) | PTGER1 | |
| SCHEMBL5120726 | 0.79 | PTGER1 (0.42) | PTGER1SCN8ASCN10A | |
| SCHEMBL5129716 | 0.78 | PTGER1 (0.43) | PTGER1SCN8ASCN10A | |
| SCHEMBL5125554 | 0.77 | NPC1 (0.41) | PTGER1SCN8ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522890-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522890-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522890-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160068491-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160068491-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160068491-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. | 2016-03-10 | — | — | US | disclosed |
| EP-2966064-A1 | PYRAZOLE-3-CARBOXYLIC ACID COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966064-A1 | PYRAZOLE-3-CARBOXYLIC ACID COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9090566-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090566-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090566-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| WO-2013101733-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20130165492-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165492-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165492-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165492-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | PTGER1 1/4885SCN8A 3998/4885SCN10A 3898/4885 |
| US-20160068491-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | PTGER4, PTGER1, GRK4 | PTGER1 2/4885SCN8A 3938/4885SCN10A 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.